02:01 PM EDT, 03/11/2025 (MT Newswires) -- Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each falling about 1.5%.

The iShares Biotechnology ETF (IBB) dropped 2.6%.

In corporate news, Guardant Health ( GH ) was up about 16% after the Centers for Medicare & Medicaid Services approved Advanced Diagnostic Laboratory Test status for its Shield blood test for colorectal cancer screening.

Quanterix ( QTRX ) shareholder Kent Lake said it opposed the firm's proposed deal with Akoya Biosciences ( AKYA ) . Quanterix ( QTRX ) was up 2%, and Akoya gained 3.3%.

Arvinas ( ARVN ) and Pfizer ( PFE ) said a phase 3 trial of vepdegestrant to treat advanced or metastatic breast cancer met its primary endpoint in the estrogen receptor 1-mutant population, but didn't reach statistical significance in progression-free survival improvement in the intent-to-treat population. Arvinas ( ARVN ) tumbled 51%, and Pfizer ( PFE ) was down 2.5%.